Kymera Therapeutics, Inc. (NASDAQ: KYMR) shares ended the last trading session 23.4% higher at $39.44. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.7% loss over the past four weeks. Shares gained following the company's announcement that partner Sanofi intends to rapidly expand the ongoing mid-stage studies on KT-474 (SAR444656) toward pivotal studies. The candidate is in phase II studies for hidradenitis suppurativa and atopic dermatitis.  Sanofi informed Kymera about the decision to expand the study after a review of preliminary safety and efficacy data in ...